Avivagen Announces CEO Letter to Shareholders
OTTAWA, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV) ("Avivagen") is pleased to announce its 2019 letter to shareholders by Chairman and interim CEO Kym Anthony.
To our shareholders:
As the consumer, scientific and regulatory climates continue to support the opportunity for Avivagen's unique and propriety technology, we are committed to driving adoption of our lead product, OxC-beta„¢, an antibiotic free alternative. Years of validated science has gone into develop...